Black Titan Corp: Stablecoin Payments Shift From Supply Growth to Network Utilization and Machine-Native Commerce

The US State Department approved a potential $24.3B sale of 48 F-35 fighter jets to Saudi Arabia, pending congressional review. Experts emphasize preserving Israel's military edge and addressing Saudi-China defense ties before finalizing the deal. Lockheed Martin and Pratt & Whitney are key contractors. The sale aims to strengthen regional security but faces scrutiny over technology transfer risks.

IperionX (IPX) validated its GenX titanium production platform, achieving a sixfold increase in throughput and 75% energy reduction. The system processed 500 kg of titanium powder in four runs. The US Army awarded IPX a $99M contract for domestic titanium production. IPX aims to scale the technology for broader applications.

AstraZeneca (NYSE: AZN) reported positive late-stage trial results for tozorakimab, a COPD drug that reduced flare-ups by 30%. The company forecasts over $5B in peak annual sales, with FDA decision expected in Q1 2027. Tozorakimab may target a broader patient population than existing biologics, supporting AstraZeneca's $80B revenue goal by 2030. However, regulatory approval and market differentiation remain key challenges.

AMD plans to raise chip prices by 10% in Q4 2026, affecting AI accelerators, GPUs, and motherboard chipsets. The increase is due to TSMC's wafer price hikes, which AMD cannot absorb. Motherboard manufacturers may pass costs to consumers. CPUs are excluded to maintain market share against Intel, but future hikes are likely.

UBS analyst Karl Keirstead raised Palantir's (PLTR) price target to $250 from $220, citing strong demand and AI sovereignty trends observed at Palantir's AIPCon11 event. The new target implies 44% upside from the Sept. 14 closing price of $173. Keirstead highlighted Palantir's expanding commercial use and robust Q2 results, including $3.4B in bookings and a 157% net dollar retention rate. This is UBS's third upward revision this year, contrasting with the broader analyst consensus of a $194 aver

Meta (META) launched Muse, an AI agent that can manage emails, payments, and other tasks, with subscription plans ranging from free to $100/month. The agent is available in the U.S. and can access various apps, but faces internal concerns over data security and reliability. Meta expects over $130B in AI infrastructure spending this year, aiming to diversify revenue beyond advertising.